ERBB2 and breast cancer: Recent small studies have reported that hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with a high OncotypeDX recurrence score (RS) achieve a pCR rate of 9.6%–27.5% and that there were inconsistent findings regarding the association between RS and pCR5–10.